The class of cancer immunotherapy drugs which target the protein PD-1 is proving to be effective against advanced liver, head and neck, lung and colon cancers.
Merck's Keytruda demonstrated a 62% tumor shrinkage in patients with advanced colon cancer containing a newly discovered genetic biomarker.The tumor response rate to Bristol's Opdivo in patients with advanced liver cancer was 19%. The overall survival rate at 12 months was 62%. While early, the results suggest Opdivo may have a role to play in the treatment of the disease where only a single targeted drug has proven effective.In a study of patients with head and neck cancer, Merck's Keytruda demonstrated a tumor response rate of 25%, or more than double the response typically seen with Eli Lilly's Erbitux.In the only randomized study discussed Friday enrolling patients with advanced, non-squamous, non-small cell lung cancer (the most common form of lung cancer) treatment with Bristol's Opdivo led to a 27% reduction in the risk of death compared to a placebo. Patients with tumors expressing high levels of the protein PD-1 lived even longer.
Via Krishan Maggon